We’ve Been Looking at Biospecimen Lifecycle All Wrong—Here’s Why That Needs to Change
- Elena Sinclair
- Mar 17
- 7 min read
For decades, the biospecimen lifecycle has been treated as a straightforward, linear process: collect, store, analyze, and discard. It’s a workflow that has remained largely unchanged, deeply rooted in pathology and clinical research traditions. In pathology, biospecimens are collected primarily for diagnostic purposes—tissues are extracted, preserved, examined under a microscope, and then either stored for limited future use or discarded. This structured, stepwise approach made sense in the past when biospecimens were primarily used for immediate diagnostic evaluation rather than long-term research.
Yet biospecimen science has evolved, and today’s research needs have far surpassed what this traditional framework was designed to support. In the world of biomarker-driven drug development, precision medicine, and multi-omics research, samples are not just static assets—they are dynamic resources that hold long-term value.
But, the industry still treats biospecimens as if their purpose begins only at collection, overlooking the crucial decisions before that moment.
So … What’s Really Missing?
Imagine you’re having a baby. Hospital. Bright lights. Busy nurses and doctors in blue scrubs. Then, at last, the moment arrives. The baby is here! You hear her first cry. Everyone is celebrating, looking forward to a long and happy life together.
And yet… no one in that room needs a biology degree to know that this baby’s story didn’t start in the delivery room. Maybe it began with a romantic dinner, with Barry White playing in the background. Then came the rush for a pregnancy test, doctor visits, genetic screenings, a baby shower—the list goes on.
Now, let’s flex our imagination muscle and think of a freshly collected biospecimen as that newborn baby. Would you still insist that its lifecycle starts at the moment of collection? Or would you—maybe reluctantly—admit that we’ve been looking at this all wrong?
Biospecimen science has evolved, and today’s research needs have far surpassed what this traditional framework was designed to support
The Problems with the Traditional Biospecimen Lifecycle
It starts too late – Focusing on biospecimen collection as the first step overlooks the importance of biomarker selection and pre-collection strategy.
It has limited foresight – Samples are often collected without a clear plan for secondary use, leading to wasted resources.
It has multiple logistical gaps – Without strategic biospecimen planning, issues like improper storage conditions or lack of metadata can and often does compromise sample integrity.
It carries regulatory risks – Poor planning can result in compliance challenges, impacting study reproducibility and regulatory approvals.
Just as a well-planned life—from conception to the grave—usually leads to greater success and fulfillment, a carefully designed biospecimen lifecycle ensures better research outcomes. The more thought and attention we give to each stage, the more reliable and impactful our clinical trial results will be.
It’s time to create a more holistic view of the biospecimen lifecycle. Fasten your seatbelts!
The New and Improved Biospecimen Lifecycle
To better understand the significance of each stage, let’s compare it to something we all know—the human lifecycle.
Human Life Stage | Biospecimen Lifecycle Stage | Rationale |
Conception (Genetic blueprint, foundational decisions, potential begins to form) | Biomarker Selection | Just as conception defines genetic traits and possibilities, biomarker selection determines the scientific foundation for biospecimen collection and use. |
Prenatal Development (Formation, preparation for viability, critical structural development) | Biospecimen Planning | Like prenatal development shaping a baby’s future, biospecimen planning ensures all logistics, protocols, and regulatory aspects are in place for successful collection. |
Birth (Transition from womb to independent existence, requiring immediate care and monitoring) | Biospecimen Collection | The moment the biospecimen is removed from the patient or donor, it enters the world and requires precise handling to ensure viability. |
Infancy & Toddlerhood (Rapid development, foundational growth, dependency on caregivers for survival and care) | Biospecimen Processing (Stabilization, preparation, quality control) | Just as infants require nurturing and basic needs to be met, biospecimens must be properly processed, stabilized, and quality-controlled to ensure future usability. |
Childhood (Skill-building, increasing independence, learning structure and routine) | Biospecimen Shipment (Transition to external use, transportation, chain of custody) | Like a child learning to navigate structured environments (school, social settings), biospecimens are transported under carefully controlled conditions to ensure integrity. |
Adolescence (Identity formation, refinement, waiting for the right opportunity to step into the world) | Biospecimen Storage (Short-/Long-Term preservation, holding for future use) | Adolescence is often a preparatory phase where individuals are preserved for future contributions—similar to biospecimens awaiting analysis. |
Early Adulthood (Testing abilities, career-building, peak activity phase) | Biospecimen Analysis (Testing, data generation, hypothesis validation) | Like a young adult proving their abilities, biospecimens now undergo rigorous testing to extract meaningful scientific data. |
Middle & Late Adulthood (Refinement of expertise, legacy-building, passing down knowledge, continued contributions in new ways) | Biospecimen Extended Use (Reuse in secondary research, retrospective studies, meta-analyses, data integration for future work) | Like individuals in later life sharing knowledge and contributing beyond their primary careers, biospecimens continue to provide value beyond their original study, supporting further research and discoveries. |
Death (Final stage, respectful closure, remains may contribute to research or understanding) | Biospecimen Destruction (Ethical Disposal, archival decisions) | At the end of its lifecycle, the biospecimen is either ethically discarded or used in final analyses, akin to human legacy and remembrance. |
And there you have it—the upgraded end-to-end biospecimen lifecycle that prioritizes deeper planning and foresight, ensuring that every sample entrusted to us by patients is used thoughtfully, strategically, and to its fullest potential.
What the New Lifecycle Seeks to Achieve
Maximizing every biospecimen’s value to honor donor contributions
Every biospecimen comes from a person who made a conscious choice to contribute to science—whether a patient in a clinical trial, a healthy volunteer, or an individual undergoing medical treatment. We owe it to them to handle their donations with respect, transparency, and purpose.
By rethinking the biospecimen lifecycle, we ensure that:
Every sample is used to its fullest scientific potential, maximizing its research contributions rather than being stored indefinitely or wasted.
Specimens are not treated as disposable assets but as valuable resources that should be thoughtfully collected, carefully managed, and strategically repurposed when possible.
Patients' trust is honored by ensuring their contributions have lasting impact, whether in immediate studies, future discoveries, or retrospective analyses that could shape new treatments.
A well-designed biospecimen lifecycle is not just about operational efficiency—it’s about respecting the human contribution behind every sample and ensuring that no donation goes to waste.
Just as a well-planned life—from conception to the grave—usually leads to greater success and fulfillment, a carefully designed biospecimen lifecycle ensures better research outcomes
Expanding Biospecimen Utility for Long-Term Scientific Impact.
Biospecimens are often collected for a single, immediate purpose, but their true value extends far beyond one use or study. A well-planned biospecimen lifecycle ensures that each sample is preserved, documented, and made accessible for multi-use and future research, unlocking its full scientific potential.
By integrating multiuse planning from the start, we:
Reduce redundant collections, minimizing the burden on patients and sites and optimizing resource use.
Enable cross-study applications, allowing biospecimens to support multiple research efforts, from biomarker discovery to drug development and retrospective analyses.
Enhance scientific efficiency, ensuring valuable samples are not underutilized or lost due to poor planning.
Support future breakthroughs, making biospecimens available for emerging technologies, AI-driven research, and evolving scientific priorities.
A biospecimen’s potential shouldn’t end with a single study—it should serve as a long-term asset for advancing medical research.
Preventing Costly Biospecimen Waste Through Smarter Lifecycle Planning
Poor planning in biospecimen management leads to avoidable mistakes—samples collected without proper documentation, stored under suboptimal conditions, or rendered unusable due to a lack of foresight. Every compromised or wasted biospecimen represents a lost scientific opportunity, unnecessary costs, and potentially irreplaceable patient contributions.
By implementing a more strategic biospecimen lifecycle, we:
Prevent sample loss by ensuring proper handling, storage conditions, and metadata tracking from the start.
Reduce logistical failures that lead to lost or misidentified specimens, streamlining research workflows.
Avoid regulatory noncompliance by maintaining clear documentation and ethical oversight, reducing the risk of study delays.
Improve efficiency and cost-effectiveness, saving both financial and scientific resources by eliminating the need for re-collection.
A biospecimen lost to poor planning is more than just wasted material—it’s a missed discovery, an avoidable delay, and a failure to honor the donor’s contribution.
Strengthening Data Integrity and Research Reproducibility
Biospecimens are not just physical samples—they are the primary source of scientific data. Every discovery in biomarker research, precision medicine, and disease modeling depends on the integrity of the specimens and the accuracy of their associated data. Yet, without standardized documentation, comprehensive metadata, and rigorous handling protocols, biospecimens can quickly become unreliable, unusable, or non-reproducible, undermining the very research they were meant to support.
A well-structured biospecimen lifecycle ensures that:
Comprehensive metadata is captured from the start, including patient demographics, collection conditions, and processing details, ensuring every sample is fully characterized.
Standardized protocols improve data consistency, reducing variability and enabling meaningful comparisons across studies.
Biospecimen traceability enhances quality control, ensuring researchers can verify sample provenance, handling history, and storage conditions.
Stronger data integrity leads to more reproducible research, increasing confidence in study outcomes and accelerating scientific advancements.
By recognizing biospecimens as the foundation of scientific data, not just physical materials, we ensure higher-quality research, stronger regulatory compliance, and long-term scientific reliability.
Reducing Regulatory and Compliance Risks
Regulatory expectations for biospecimen management are evolving, with new guidelines like ICH E6(R3) and ICH M11 emphasizing data integrity, traceability, and standardization in clinical research. Failure to align biospecimen practices with these requirements can lead to compliance violations, study delays, and data integrity issues that jeopardize regulatory approvals.
A strategically designed biospecimen lifecycle ensures:
Full traceability from collection to analysis, meeting ICH E6(R3) standards for data governance and quality oversight.
Standardized pre-analytical variables and metadata capture, aligning with ICH M11’s focus on structured, harmonized study data.
Stronger ethical and legal compliance, ensuring proper patient consent, secondary use authorization, and adherence to evolving global regulations.
More seamless regulatory submissions, reducing audit risks by maintaining well-documented biospecimen handling, storage, and analysis records.
As regulatory agencies raise the bar for data reliability and biospecimen governance, adopting a modernized lifecycle ensures compliance today and preparedness for future regulations.
Ensuring Strategic Long-Term Research Sustainability
Biospecimens are finite, often irreplaceable resources, yet many are underutilized, poorly preserved, or discarded prematurely due to inadequate long-term planning. A sustainable biospecimen lifecycle ensures that each sample continues to generate value long after its initial collection, supporting future discoveries and emerging research needs.
A modernized biospecimen lifecycle enables:
Proactive sample preservation strategies, ensuring specimens remain viable for secondary use, retrospective analyses, and evolving scientific advancements.
Integration with AI, multi-omics, and next-generation research, allowing biospecimens to be leveraged for discoveries beyond their original purpose.
Efficient resource utilization, minimizing the need for repeated collections and reducing patient burden.
Expanded cross-study and collaborative research potential, enabling biospecimens to contribute to global data-sharing initiatives and large-scale studies.
By treating biospecimens as strategic, reusable assets rather than single-use materials, we build a more sustainable, efficient, and forward-thinking research ecosystem.
A Smarter Way Forward
The way we think about biospecimens is long overdue for an upgrade. They’re not just vials in a freezer or one-time-use samples—they’re the foundation of scientific discovery, carrying immense potential beyond their initial study. By reimagining the biospecimen lifecycle with strategy, foresight, and sustainability in mind, we can maximize scientific impact, reduce waste, and better honor the contributions of those who make research possible.
It’s time to move beyond outdated workflows and embrace a more holistic, intelligent approach. The question is: Are we ready to rethink what’s possible?
Comments